ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,629 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentAllschwilInCephalo AG
InCephalo AG Logo
Verified· 2 sourcesTrust Score
Summary

About the company

The core activity of InCephalo Therapeutics is the development and research of local therapies for neurological diseases, particularly brain cancer. The company focuses on the development of biological drugs specifically designed for local application in the central nervous system (CNS) to minimize side effects and maximize efficacy. The proprietary Compartment Lock technology (C-Lock) enables the local retention of biological drugs in the CNS, prolonging their effect while minimizing systemic exposure.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
4.0/5

InCephalo AG

✓ Offered5
C-Lock™ Platform
Compartment-locked biologics for local CNS therapies; development of constructs with reduced FcRn binding, prolonged retention in the brain and rapid systemic clearance.
C-Locked Biologics
Local biological therapeutics for brain tumours; precise immune activation without systemic exposure, designed for safe and effective treatment of CNS diseases.
Glioblastoma Therapy (InC01)
Cytokine-based therapy for glioblastoma with local immune activation, increased dosing control and no systemic toxicity; lead asset in clinical development.
Therapies for Paediatric High-Grade Gliomas and DIPG
Planned clinical expansion of the platform for paediatric high-grade gliomas and DIPG based on the C-Lock technology.
Therapies for Neuroinflammation and Neurodegeneration
Potential application of the modular C-Lock platform to conditions beyond tumours, in particular neuroinflammation and neurodegeneration.
Trust & reputation

ranQ Trust Score of InCephalo AG: 4.0 out of 5.0

Trust Score4.0/ 5.0

High

x

Data basis 54% · As of October 2026

InCephalo AG has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
InCephalo AG scores 70.4 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.64.612%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
InCephalo AG scores 83.3 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).83.322%
InCephalo AG scores 25.7 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.25.74%
  • Media authority: No data point — the criterion is taken out of the weighting and does not lower the score.—4%
Qualifications+0.00

InCephalo AG reaches a ranQ Trust Score of 4.0 out of 5.0 — rated «High». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 54%, so the score is backed by part of the criteria. As of October 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Knowledge

No knowledge articles yet

Once InCephalo AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

InCephalo AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank InCephalo AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of InCephalo AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Hegenheimermattweg 167A
4123 Allschwil

At a glance

Legal form
Corporation
UID
CHE-473.675.319
Founded
2021 · 5 years
Last commercial register change
June 10, 2026
Employees
1 to 10
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
    • Full methodology

    Similar companies

    GG
    GlioCART GmbH
    Allschwil
    NB
    Nanolynx Biologics AG
    Allschwil
    AP
    Actelion Pharmaceuticals Ltd
    Allschwil
    MH
    Monix Health AG
    Allschwil
    PS
    Pharmatrans Sanaq AG
    Allschwil
    GG
    Gubra GmbH
    Allschwil
    IT
    Immuna Therapeutics AG
    Allschwil
    OA
    OncoGenomX AG
    Allschwil